EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Addition of ruxolitinib in Graft‐versus‐Host disease prophylaxis for pediatric β‐Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study

Xiuli Hong iD, Yamei Chen, Jingyuan Lu, Quanyi Lu

Pediatric Transplantation · 2023

DOI: 10.1111/petr.14466 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pediatric Transplantation, 2023. Verfasst von Xiuli Hong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongshan Hospital Xiamen University, Xiamen, China. Hauptthemen laut MEDLINE: beta-Thalassemia, Epstein-Barr Virus Infections, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Project of Fujian Province, Scientific research program of Xiamen City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the effect of addition of ruxolitinib in Graft‐versus‐Host Disease (GVHD) prophylaxis on pediatric patients with β‐thalassemia major after allogeneic hematopoietic stem cell transplantation(HSCT).

Methods

This retrospective study reviewed 49 consecutive β‐thalassemia major pediatric patients who underwent HSCT from unrelated or haploidentical donors from February 2018 to October 2022. All transplantation recipients received cyclosporine A (CsA), mycophenolate mofetil (MMF), and short‐term methotrexate (MTX) as GVHD prophylaxis; while 27 of them in the ruxolitinib group had added ruxolitinib oral to GVHD prophylaxis regimen at 2.5 mg twice daily once successful engraftment after January 2020.

Results

The outcome showed that the ruxolitinib group had a lower cumulative incidence than the control group regardless of acute GVHD (22.2% vs.40.9%; p = .153) or chronic GVHD (18.5% vs.40.9%; p = .072); especially, the incidence of grade III‐IV acute GVHD was reported significantly less frequently in ruxolitinib group than that of the control group (0 vs. 27.3%, p = .005). No significant difference was detected between the two groups in EBV (Epstein–Barr virus)/CMV (cytomegalovirus) reactivation and BKV (BK virus) infection ( p = .703, 1.000, and .436, respectively). Twenty‐six patients (96.3%) in the ruxolitinib group were alive, while two patients (9.1%) in the control group died of intestinal acute GVHD. The 2‐year overall survival (OS) and thalassemia‐free survival (TFS) were both 96.296% in the ruxolitinib group, while both 90.909% in the control group.

Conclusion

This study reveals that ruxolitinib prophylaxis is a promising option to decrease the incidence of grade III‐IV acute GVHD in pediatric patients with β‐thalassemia major.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaEpstein-Barr Virus InfectionsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansChildRetrospective StudiesHerpesvirus 4, HumanNitrilesPyrazolesPyrimidines

Stichwörter der Autor:innen

graft versus host diseasehematopoietic stem cell transplantationprophylaxisruxolitinibthalassemia

Substanzen

ruxolitinibNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Hematology, Zhongshan Hospital Xiamen University, Xiamen, China.

ORCID-Profile: Xiuli Hong

Förderung

  • Science and Technology Project of Fujian Province
  • Scientific research program of Xiamen City

Zitieren

APA

Hong, X., Chen, Y., Lu, J., & Lu, Q. (2023). Addition of ruxolitinib in Graft‐versus‐Host disease prophylaxis for pediatric β‐Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study. Pediatric Transplantation. https://doi.org/10.1111/petr.14466

Vancouver

Hong X, Chen Y, Lu J, Lu Q. Addition of ruxolitinib in Graft‐versus‐Host disease prophylaxis for pediatric β‐Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study. Pediatric Transplantation. 2023. doi:10.1111/petr.14466

BibTeX
@article{Hong2023,
  author = {Hong, Xiuli and Chen, Yamei and Lu, Jingyuan and Lu, Quanyi},
  title = {Addition of ruxolitinib in Graft‐versus‐Host disease prophylaxis for pediatric β‐Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study},
  journal = {Pediatric Transplantation},
  year = {2023},
  doi = {10.1111/petr.14466}
}
Kostenlos starten →